Friday November 27 2009 | Biotechnology feed | All feeds
|
|
Friday November 27 2009 | Biotechnology feed | All feeds
|
|
|
IL-2 antibodies as an effective treatment of ulcerative colitis Intestinal
inflammation can occur in a number of pathologies, perhaps the most serious of
which is inflammatory bowel disease (IBD). IBD is an umbrella term used to
describe two distinct clinical conditions, ulcerative colitis and Crohn's
disease, both of which are chronic digestive diseases resulting from an
abnormal immune system response to stimuli in the digestive tract. In 2001, the
number of prevalent cases of IBD was been estimated to have totaled over 1.5
million in the major pharmaceutical markets. Currently in excess of $0.5
billion, IBD related sales have been forcasted to increase by 3-10% each year
for the next 5 years. Current treatment options are sub-optimal and the
present focus is on the identification of inflammatory mediators involved in
IBD. A greater understanding of inflammatory pathways and new "biologic
agents" that will emerge from this knowledge will expand the IBD market
and provide improved options for the patient. One treatment
option for ulcerative colitis is cyclosporine that acts by inhibiting
interleukin-2 (IL-2) production. A more direct approach is the use of IL-2
receptor blockers. A number of IL-2 receptor antibodies have been developed
including Novartis’ basiliximab and Biotest’s inolimomab; the former has
been launched while the latter is in phase III trial for the prevention of
transplant rejection. To our knowledge IL-2 receptor antibodies have yet to
enter clinical evaluation for the treatment of IBD. University of
Leuven researchers have therefore recently addressed this issue by conducting
a pilot trial to determine the efficacy and safety of a third humanized
anti-IL2 antibodies daclizumab in ulcerative colitis patients. This antibody
was first launched in 1997 by Roche for the prevention of transplant
rejection. Leuven researchers have now published data from an open label pilot
study of refractory ulcerative colitis. Ten patients with chronically active
ulcerative colitis were treated twice over a period of 8 weeks with 1 mg/kg
daclizumab. This protocol decreased clinical activity by over 50%. Likewise,
endoscopic scores were also significantly decreased at wk 8 while quality of
life was improved. This pilot study prompts the design of larger scale
clinical evaluations of daclizumab and other IL-2 receptor antibodies. Adapted from Van Assche et al, Am J Gastroenterol 2003 Feb;98(2):369-76 - Interested in collaborating with this group? Contact LeadDiscovery or the authors direct.
Interested in collaborating with this group? Contact leaddiscovery@bioportfolio.co.uk Projects such as these are overviewed in full DiscoveryDossiers. LeadDiscovery and BioPortfolio aims to provide reliable, insightful analysis on the biotechnology industry. However, this information is provided "as is" and no representations or warranties either express or implied of completeness, accuracy, or of any other nature are made with respect to this information. This information is neither an offer to sell nor a solicitation to buy the securities of any company. This information contains forward-looking statements, which involve risks and uncertainties which may not be listed. The biotechnology industry is an emerging industry and the securities of the companies mentioned in this report have a very high degree of risk and volatility. For this reason, this information is supplied on the condition that the reader will make his or her own determination as to its suitability for any purpose prior to any use of this information. The employees and officers of LeadDiscovery and BioPortfolio may hold positions in some or all of the stocks discussed in this report. This abstract has been produced by LeadDiscovery Ltd. Founded by life scientists for life scientists we aim to help industry identify cutting edge drug discovery options and academic/biotech institutions maximize the potential of their research. Abstracts strictly reflect the opinion of LeadDiscovery's editorial panel. While all reasonable efforts are made to ensure the accuracy of information provided LeadDiscovery and the publisher BioPortfolio, takes no responsibility for incorrect or misleading information. LeadDiscovery is designed for educational and drug development purposes only and is not intended or designed to offer medical advice or advice of any sort, and must not be used for such purpose. The information provided through LeadDiscovery and BioPortfolio should not be used for diagnosing or treating a health problem or a disease and no reliance should be placed on any information contained in this abstract or elsewhere on LeadDiscovery's and BioPortfolio's website. It is not intended to be a substitute for professional care. If you have or suspect you may have a health problem, you should consult your physician or other health care provider. |
|
|
